--- title: "Telomir Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286456110.md" datetime: "2026-05-14T19:12:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286456110.md) - [en](https://longbridge.com/en/news/286456110.md) - [zh-HK](https://longbridge.com/zh-HK/news/286456110.md) --- # Telomir Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.03. EBIT: As of FY2026 Q1, the actual value is USD -1.092 M. #### Segment Revenue Telomir Pharmaceuticals, Inc. currently has no source of revenue, reporting $0 for both the three months ended March 31, 2026, and March 31, 2025. #### Operational Metrics - **Net Loss**: Telomir Pharmaceuticals, Inc. reported a net loss of -$990,947 for the three months ended March 31, 2026, an improvement from a net loss of -$2,179,828 for the same period in 2025. - **Total Operating Costs**: Total operating costs decreased to $1,041,336 for the three months ended March 31, 2026, from $2,187,782 in the prior year period. - **General and Administrative Expenses**: These expenses were $573,539 for the three months ended March 31, 2026, significantly down from $1,850,786 for the same period in 2025, primarily due to lower stock compensation expense. - **Research and Development Expenses**: These expenses increased to $467,797 for the three months ended March 31, 2026, compared to $336,996 for the same period in 2025, driven by toxicology, preclinical research, and R&D consultants. - **Other Income, Net**: Total other income, net, increased to $50,389 for the three months ended March 31, 2026, up from $7,954 in the prior year, primarily due to higher interest income. - **Interest Income**: Interest income was $51,644 for the three months ended March 31, 2026, compared to $8,000 for the same period in 2025. - **Interest Expense**: Interest expense was -$1,255 for the three months ended March 31, 2026, compared to -$46 for the same period in 2025. #### Cash Flow - **Net Cash Used in Operating Activities**: Operating activities used -$1,773,510 of cash for the three months ended March 31, 2026, compared to -$863,132 for the same period in 2025. - **Net Cash Provided by Financing Activities**: Financing activities provided $47,351 of cash for the three months ended March 31, 2026, primarily from proceeds of an insurance loan, partially offset by repayments to executive officers and insurance loans, with no financing activities in the comparable 2025 period. - **Cash and Cash Equivalents**: As of March 31, 2026, Telomir Pharmaceuticals, Inc. had cash and cash equivalents of approximately $5.6 million. #### Future Outlook and Strategy Telomir Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics, with its lead candidate, Telomir-1 (Telomir-Zn), targeting biological pathways in cancer and age-related diseases, and has received FDA clearance for an IND application for Telomir-Zn in advanced or metastatic triple-negative breast cancer (TNBC). On April 22, 2026, Telomir Pharmaceuticals, Inc. acquired TELI Pharmaceuticals, Inc., consolidating exclusive worldwide rights to develop and commercialize Telomir-1 (Telomir-Zn), a transaction that included a $1.0 million cash contribution and a binding commitment for up to an additional $4.0 million equity investment contingent on achieving specific regulatory and clinical milestones for Telomir-1 (Telomir-Zn). Telomir Pharmaceuticals, Inc. expects its cash and cash equivalents to fund operations through the first quarter of 2027 and anticipates increased research and development expenses as Telomir-1 advances into clinical trials, necessitating additional funding through debt and/or equity financings in the near future due to expected losses until significant revenue from product sales is generated.From April 1, 2026, through May 13, 2026, the company sold 4,275 shares of Common Stock, generating approximately $6,000 in net proceeds through an at-the-market (ATM) offering. ### Related Stocks - [TELO.US](https://longbridge.com/en/quote/TELO.US.md) ## Related News & Research - [Faron Pharmaceuticals LTD: Holding(s) In Company](https://longbridge.com/en/news/286725255.md) - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [PMV Pharmaceuticals (NASDAQ:PMVP) Will Have To Spend Its Cash Wisely](https://longbridge.com/en/news/286912396.md) - [Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA | HNSA Stock News](https://longbridge.com/en/news/286864132.md)